Study Clarifies When to Start HIV Therapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

CHICAGO-In HIV-positive patients, antiretroviral therapy should be started when CD4+ lymphocyte counts drop below 350 cells/mL3, according to a new study reported at the 8th Conference on Retroviruses and Opportunistic Infections.

CHICAGO—In HIV-positive patients, antiretroviral therapy should be started when CD4+ lymphocyte counts drop below 350 cells/mL3, according to a new study reported at the 8th Conference on Retroviruses and Opportunistic Infections.

Jon Kaplan, of the Centers for Disease Control and Prevention, reported that of 5,110 HIV-positive individuals who started 2- or 3-drug antiretroviral therapy in 1994 or later, those who began treatment when CD4 counts had dropped below 200 cells/mL3 had a markedly increased risk of death, whereas survival rates were similar for those who began treatment in the range of 350 to 500 cells/mL3.

Based on these results, a federal panel, convened by the Department of Health and Human Services and headed by Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, has recommended that treatment start at CD4 counts of 350 cells/mL3 rather than the previously recommended 500 cells/mL3.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content